EUVIMEDOpdag EUVIMED
Open access

Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab

Tanawin Nopsopon iD, Nora A Barrett, Wanda Phipatanakul, Tanya M Laidlaw, Scott T Weiss, Ayobami Akenroye iD

Allergy · 2024

DOI: 10.1111/all.16002 ↗

At a glance

Journal article in Allergy, 2024. Written by Tanawin Nopsopon and 5 co-authors. Institution: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA. Major MEDLINE topics: Asthma, Antibodies, Monoclonal, Humanized, Omalizumab, Anti-Asthmatic Agents. Cited 11 times so far (Crossref); 65 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NIMHD NIH HHS, NHLBI NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Lung function is an independent predictor of mortality. We evaluated the lung function trajectories of a cohort of patients with asthma receiving biologic therapy.

Methods

We identified 229 monoclonal antibody‐naïve adult patients with moderate‐to‐severe asthma who initiated omalizumab, mepolizumab, or dupilumab between 2010 and 2022 in a large healthcare system in Boston, MA. Generalized additive mixed models were used to estimate the lung function trajectories during the 156 weeks following biologic initiation. Response was defined as an improvement in FEV 1 or a decrease of ≤0.5% per year. The Kaplan–Meier estimator was used to assess time to no additional improvement in FEV 1 in responders. All models were adjusted for age, sex, body mass index, smoking status, baseline exacerbation rate, and baseline blood eosinophil count.

Results

Eighty‐eight patients initiated mepolizumab, 76 omalizumab, and 65 dupilumab. Baseline eosinophil count was highest in the mepolizumab group (405 cells/mcL) and lowest for omalizumab (250 cells/mcL). Both FEV 1 and FVC improved in the mepolizumab group (FEV 1 + 20 mL/year; FVC +43 mL/year). For omalizumab, there was an initial improvement in the first year followed by decline with an overall FEV 1 loss of −44 mL/year and FVC −32 mL/year. For dupilumab, both FEV 1 (+61 mL/year) and FVC (+74 mL/year) improved over time. Fifty percent of the mepolizumab group, 58% omalizumab, and 72% of dupilumab were responders. The median time to no additional FEV 1 improvement in responders was 24 weeks for omalizumab, 48 weeks for mepolizumab, and 57 weeks for dupilumab.

Conclusion

In this clinical cohort, mepolizumab, omalizumab, and dupilumab had beneficial effects on FEV 1 and FVC with distinct post‐initiation trajectories.

Subjects

MeSH terms (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedOmalizumabAnti-Asthmatic AgentsRespiratory Function TestsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeSeverity of Illness IndexLungCohort StudiesAged

Author keywords

asthmabiologicslung functionmonoclonal antibodiestrajectory

Substances

Antibodies, Monoclonal, HumanizedOmalizumabmepolizumabAnti-Asthmatic Agentsdupilumab

Authors and institutions

  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID profiles: Tanawin Nopsopon, Ayobami Akenroye

Funding

  • NIAID NIH HHS
  • NIMHD NIH HHS
  • NHLBI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Heart, Lung, and Blood Institute
  • National Institute on Minority Health and Health Disparities

Cite

APA

Nopsopon, T., Barrett, N. A., Phipatanakul, W., Laidlaw, T. M., Weiss, S. T., & Akenroye, A. (2024). Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. https://doi.org/10.1111/all.16002

Vancouver

Nopsopon T, Barrett NA, Phipatanakul W, Laidlaw TM, Weiss ST, Akenroye A. Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab. Allergy. 2024. doi:10.1111/all.16002

BibTeX
@article{Nopsopon2024,
  author = {Nopsopon, Tanawin and Barrett, Nora A and Phipatanakul, Wanda and Laidlaw, Tanya M and Weiss, Scott T and Akenroye, Ayobami},
  title = {Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.16002}
}
Start for free →